MasterClass: Could Glutamatergic Modulation be the Keystone of Durable Change in Treatment-Resistant Depression?

Treatment-resistant depression continues to highlight the limitations of traditional monoaminergic approaches and the need for novel therapeutic targets. This session explores the role of glutamatergic dysfunction in MDD, reviews the latest evidence supporting current and emerging glutamatergic therapies, and equips clinicians with practical strategies to incorporate these advances into evidence-based treatment planning for patients with TRD.

Supported by an educational grant from Johnson & Johnson.